Table 5. Frequencies of molecular markers of resistance to SP and AQ at baseline and at the end of the intervention period in intervention and control arms.
Molecular Markers | Baseline | Postintervention | Baseline Versus Overall Postintervention p-Value | |||||
IPTc | Placebo | |||||||
n | Percent Mutant | n | Percent Mutant | n | Percent Mutant | p-Value | ||
DHFR 51 | 48 | 62.5 | 78 | 75.6 | 148 | 66.2 | 0.144 | 0.35 |
DHFR 59 | 48 | 60.4 | 78 | 76.9 | 148 | 59.5 | 0.009 | 0.50 |
DHFR 108 | 41 | 78.0 | 76 | 78.9 | 139 | 71.2 | 0.217 | 0.58 |
DHPS 437 | 47 | 38.3 | 83 | 67.5 | 165 | 43.6 | <0.001 | 0.09 |
DHPS 540 | 45 | 0 | 82 | 7.3 | 165 | 3.6 | 0.205 | 0.82 |
Triple DHFR mutations | 41 | 58.5 | 76 | 69.7 | 139 | 54.0 | 0.024 | 0.90 |
Quadruple mutants (triple DHFR + DHPS 437) | 41 | 22.0 | 75 | 53.3 | 139 | 28.1 | < 0.001 | 0.07 |
Pfcrt-76 | 46 | 80.4 | 79 | 84.8 | 156 | 75.0 | 0.085 | 0.25 |
Pfmdr1-86 | 46 | 45.6 | 76 | 36.8 | 156 | 34.6 | 0.739. | 0.19 |
n = number of participants with parasitaemia at blood smear tested.